Pulmonary toxicity associated with bischloroethylnitrosourea (BCNU)

Area of Science:

• Oncology
• Pulmonology
• Pharmacology

Background:

• Bischloroethylnitrosourea (BCNU) is a chemotherapy agent used for treating various malignancies.
• Pulmonary fibrosis is a serious potential side effect of BCNU therapy.

Purpose of the Study:

• To investigate the incidence, clinical presentation, and outcomes of pulmonary fibrosis in patients treated with BCNU.
• To explore potential contributing factors, such as dosage and combination therapy, and the efficacy of prednisone.

Main Methods:

• Retrospective review of ten patients who developed pulmonary fibrosis post-BCNU therapy.
• Analysis of clinical symptoms, chest roentgenograms, pulmonary function tests, and autopsy findings.
• Review of existing literature on BCNU-induced pulmonary toxicity.

Main Results:

• Ten patients developed pulmonary fibrosis, with a fatality rate of 70% (7/10).
• Symptoms ranged from gradual onset cough and dyspnea to acute respiratory failure.
• Chest imaging revealed interstitial infiltrates, and pulmonary function tests showed hypoxia and restrictive defects.
• Toxicity did not appear dose-related and may be exacerbated by cyclophosphamide; prednisone was largely ineffective.

Conclusions:

• Pulmonary fibrosis is a significant and often lethal complication of BCNU therapy.
• Concomitant cyclophosphamide may increase the risk, and prednisone offers little therapeutic benefit.
• Further research into BCNU's pulmonary toxicity and management strategies is warranted.